Literature DB >> 20938429

Management of chronic pelvic pain.

A R Benjamin-Pratt1, F M Howard.   

Abstract

Chronic pelvic pain (CPP) is a common complaint of women presenting for gynecologic and primary care. Evaluation of CPP requires obtaining a careful history including not only obstetrical and gynecologic information but also screening for gastrointestinal, urologic, musculoskeletal, and neurological disorders. A detailed physical examination is also necessary. Management of CPP depends largely on the cause. Gynecologic causes include endometriosis, pelvic inflammatory disease, adhesive disease, pelvic congestion syndrome, ovarian retention syndrome, ovarian remnant syndrome, adenomyosis, and leiomyomas. Some non-gynecologic causes are interstitial cystitis/painful bladder syndrome, irritable bowel syndrome, pelvic floor tension myalgia, and abdominal myofascial pain syndrome. Treatments may be directed toward specific causes or may be targeted to general pain management. The most effective therapy may involve using both approaches. The diagnosis and treatment of each of the above disorders, and the management of CPP itself, is discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20938429

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  2 in total

1.  Evaluation of the Diagnostic Accuracy of the Interview and Physical Examination in the Diagnosis of Endometriosis as the Cause of Chronic Pelvic Pain.

Authors:  Jolanta Nawrocka-Rutkowska; Iwona Szydłowska; Aleksandra Rył; Sylwester Ciećwież; Magdalena Ptak; Andrzej Starczewski
Journal:  Int J Environ Res Public Health       Date:  2021-06-19       Impact factor: 3.390

2.  Anatomical landmarks of the intra-pelvic side-wall as sources of pain in women with and without pregnancy-related chronic pelvic pain after childbirth: a descriptive study.

Authors:  Thomas Torstensson; Stephen Butler; Anne Lindgren; Magnus Peterson; Lena Nilsson-Wikmar; Margaretha Eriksson; Per Kristiansson
Journal:  BMC Womens Health       Date:  2018-03-27       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.